Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab combinations in gastric/GEJ cancer
NCT07110571Phase 2Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Suzhou Suncadia Biopharmaceutical. Started Aug 2025; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07110571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07110571.